CD8A and acute myeloid leukemia: In fact, there is evidence that, in AML patients relapsing after an allogeneic hematopoietic stem cell transplant (allo-HSCT), the administration of sorafenib induces an increased bone marrow (BM) infiltrate of T CD8+CD279+ “exhausted” lymphocytes [57].